openPR Logo
Press release

Viral Inactivation Market Set to Surge Significantly During 2025

09-28-2017 01:25 PM CET | Health & Medicine

Press release from: TMR - Research Reports

Viral Inactivation Market Set to Surge Significantly During

As per a report by Transparency Market Research, the global viral inactivation market will likely rise at a healthy 7.4% during the period between 2017 and 2025. Rising at this rate, the market will likely become worth US$5.736 bn by 2025 from US$3.05 bn in 2016.

Various methods have been developed and many more are under trial for viral inactivation during biopharmaceutical production and for blood and blood derived products. Depending upon the methods, the main segments of the global viral inactivation market are chemical, radiation, and others such as pasteurization, dry and moist heat treatment. Among them, the segment of radiation method for viral inactivation will likely outpace all others vis-à-vis growth rate in the near future because of the increasing uptake of UV-radiation equipment by the blood centers in developed countries of the U.S., the U.K, Germany, France, Italy, etc.

View and Download TOC of Viral Inactivation Market Research Report@ https://www.transparencymarketresearch.com/report-toc/21497

Depending upon geography, the key segments of the global viral inactivation market are North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Of them, North America holds a leading share in the market on account of solid demand for blood and blood products and vaccine in this region. The market in the region is predicted to rake in a revenue of US$2.31 bn by 2025.

New Drugs Approval Boosts Chances to Earn Higher Revenue

Approval of new drugs, regulatory guidelines framed by regulatory authorities for the viral safety of biologics products, and rapid growth of biologics and biosimilars industry are slated to provide a major impetus to the global market for viral inactivation.

“The demand for biosimilars products has growing rapidly in both developed and developing countries due to need for cost effective generic treatment alternative to high cost branded biologics. In fact, biopharmaceutical products worth over hundreds of billions of dollars will go off patents in the near future and this will provide a major boost to the market,” explains the lead analyst of the report.

Besides the increasing occurrence of infectious diseases and growing application of biosimilars therapeutic treatment for a range of diseases will also serve to have a positive influence on the market.

Development of Vaccines for New Viruses to Provide Avenues for Growth

Posing a challenge to the market, on the flipside, is the steep cost of developing and manufacturing biologics and biosimilars products and also the expensiveness of equipment for viral inactivation. However, emergence of new viruses and development of vaccines against these viruses and development and adoption of newer viral inactivation methods is expected to open up new avenues of growth in the market.

This review is based on the findings of a TMR report, titled, “Viral Inactivation Market (Method – Chemical and Radiation; Application – Blood and Blood Products, Vaccines, and Cell and Tissue Culture; End-user - Pharmaceutical and Biotechnology Companies, Blood Banks and Hospitals, and Contract Research Organizations) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017–2025.”

Request and Download Sample Report@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=21497

Some of the dominant players in the global market for viral inactivation are Shandong Weigao Group Medical Polymer Company Limited, Merck & Co, Sartorius AG, Cerus Corporation, Macopharma SA, Terumo BCT, Inc., Thermo Fisher Scientific Inc., and V.I.P.S. SA. Merck & Co., Inc. among them, held a leading share in the market in 2016. The reasons behind its dominant position are a solid geographical outreach and strategic acquisitions.

Other keen companies operating in the global market for viral inactivation are also leveraging carefully-considered acquisitions to bolster their positions. They are also expending time and money into development of new products to cater to the different needs of the population.

Buy Full Viral Inactivation Market Report@ https://www.transparencymarketresearch.com/checkout.php?rep_id=21497<ype=S

About TMR

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Viral Inactivation Market Set to Surge Significantly During 2025 here

News-ID: 746143 • Views:

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1.07 Billion by 2024
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million by 2024
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for Viral

Viral Inactivation Market Growing Demand of Kits and Reagents Viral Inactivation …
According to Precision Business Insights (PBI), the latest report, the Viral Inactivation market is expected to be worth USD 2.1 billion in 2022, growing at a 12.8% CAGR from 2022 to 2028. The primary driver of the expansion of the global Viral Inactivation market are speedy growth in pharmaceutical and biotechnology industries and strong inclination of R&D investments in life sciences industry. View the detailed report description here - https://precisionbusinessinsights.com/market-reports/viral-inactivation-market/ Kits &
Global Anti-Viral Drug Therapy Market | Global Anti-Viral Drug Therapy Industry …
Anti-viral drug therapy market comprises of sales of branded & generic anti-viral drugs and related services by entities that manufacture the branded or generic anti-viral drugs for treating microbial infections. Anti-viral drug therapy industry includes several establishments that manufacture anti-viral drugs, which are used to treat diseases caused by viral infections. Examples of antiviral drugs include cidofovir, amantadine, zanamivir, idoxuridine, famiciclovir, tenofovir, adefovir and ribavirin. According to study, “Anti-Viral Drug Therapy
Viral Antigens Market to Reap Excessive Revenues by 2028(Based on product type, …
Antigens are commonly referred to as substances that are capable of triggering an immune response in a host by activating the lymphocytes or initiating antibody production against infections. Depending upon the fact that they either enter the human body or originate within the body, viral antigens are classified as foreign or self-antigens respectively. Among these, self-antigens comprise mutated or overexpressed proteins. However, foreign antigens are likely to include bacteria, parasites,
Viral Vector and Plasmid DNA Manufacturing Market - Increase In Awareness Regard …
The Viral Vector and Plasmid DNA Manufacturing Market is expected to reach $ 1,090 million in 2023, growing at an annual average rate of 22.6% from 2017 to 2023. North America was the largest contributor to the viral vector and plasmid DNA markets in 2016. However, the Asia Pacific region is expected to have the highest growth rate during the forecast period. Gene therapy has included tools such as viral vectors
Viral Vaccines Market : Challenges and Opportunities Against Viral Diseases
Vaccines are biotic compositions. They are basically formulated from living beings that increase the resistance against a specific illness. Vaccinations that help in avoiding the occurrence of specific diseases are known as prophylactic vaccines and in other instance, the vaccines that are helpful in treating the disease are called therapeutic vaccines. A vaccine is generally produced by using a weakened or murdered type of the sickness causing microorganism. The agent
Global Viral Molecular Diagnostics Market
The Viral Molecular Diagnostics Market reportprovides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies. Molecular diagnostics refers to a technique used to detect and identify the presence of genetic material or proteins associated with a specific health condition or disease. Viral molecular diagnostic helps in